Evaluation of and expected access to new RSV vaccines and long-acting monoclonal antibody (mAB) in Australia as at 7 May 2024

RSV vaccine/mAB	Indication	Therapeutic Goods Administration (TGA) approval (registration)	Pharmaceutical Benefits Advisory Committee (PBAC) assessment for funding	National Immunisation Program inclusion/funded supply	Private market supply	Clinical guidance
Infant protection						
Nirsevimab (Beyfortus, Sanofi-Aventis; long-acting monoclonal antibody)	**Newborns/infants and children up to 24 months of age with risk conditions**	**TGA approved in November 2023**	**July 2024**	**State-funded programs:** • New South Wales • Queensland • Western Australia	**No**	**ATAGI statement**
Abrysvo (Pfizer; protein subunit vaccine)	**Infants from birth through 6 months of age, by active immunisation of pregnant individuals**	**TGA approved in March 2024**	**March 2024 – not currently considered cost-effective by PBAC**	**No (PBAC nominated the Early Resolution re-submission pathway for this item)**	**TBD**	**TBD**

RSV vaccine/mAB	Indication	Therapeutic Goods Administration (TGA) approval (registration)	Pharmaceutical Benefits Advisory Committee assessment for funding	National Immunisation Program inclusion/funded supply	Private market supply	Clinical guidance
Older adult protection						
Abrysvo (Pfizer; protein subunit vaccine)	**Adults aged ≥60 years**	**TGA approved in March 2024**	**TBD**	**TBD**	**TBD**	**TBD**
Arexvy (GSK; protein subunit vaccine with adjuvant)	**Adults aged ≥60 years**	**TGA approved in January 2024**	**July 2024**	**TBD**	**Available**	**ATAGI clinical statement**
Moderna (Moderna RSV mRNA-1345 vaccine)	**Adults aged ≥60 years**	**Submitted**	**TBD**	**TBD**	**TBD**	**TBD**